

Warning Time and Patient Centred Goals with Transdermal Oxybutynin

Submission date 08/11/2005	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 24/11/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 21/12/2011	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Linda Cardozo

Contact details
8 Devonshire Place
London
United Kingdom
W1G 6HP

Additional identifiers

Clinical Trials Information System (CTIS)
2005-005009-41

Protocol serial number
EUDRACT 2005-005009-41

Study information

Scientific Title

Acronym

WTPCGTO

Study objectives

Transdermal oxybutynin reduces urinary warning time, and helps patients achieve their goals for treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Pending from King's College Hospital Research Ethics Committee

Study design

Double blind randomised controlled trial (RCT)

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Overactive bladder

Interventions

Transdermal Oxybutynin or Placebo Patch

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Oxybutynin

Primary outcome(s)

Achievement of goals score

Key secondary outcome(s)

1. Change in King's Health Questionnaire (KHQ) scores (by domain and total)
2. Change in mean, median and minimum warning time
3. Compliance with medication
4. Change in episodes of urgency/urge incontinence
5. Change in frequency/nocturia

Outcomes assessed by 3 day bladder diaries incorporating Patients Perception of Intensity of Urgency Scale (PPIUS)

Completion date

01/12/2007

Eligibility

Key inclusion criteria

At study entry:

1. Female patient aged ≥ 18
2. Written informed consent obtained
3. Patient is willing and able to complete the frequency volume chart (FVC) and questionnaires correctly
4. Symptoms of overactive bladder (frequency/urge/urge incontinence) for ≥ 3 months AND/OR previously demonstrated detrusor overactivity (DO) at urodynamics

At randomisation:

1. At least three episodes of urgency or urge incontinence on FVC over 3 days
2. At least frequency ≥ 8 on FVC over 3 days

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Key exclusion criteria

At study entry:

1. History of allergy to oxybutynin or any of the ingredients of Kentera
2. History of allergy from medical tape or transdermal skin patch
3. Pregnancy, intention to become pregnant during study period, unreliable contraception despite being sexually active, breast feeding
4. Urodynamic proven mixed incontinence
5. Voiding difficulties (flow rate < 15 ml/s, or post void residual > 50 ml)
6. Patient with indwelling catheter or practicing clean intermittent self-catheterisation (CISC)
7. Evidence of current urinary tract infection (UTI) or bladder stone or malignancy
8. Uncontrolled narrow angle glaucoma, myasthenia gravis, gastric or urinary retention, renal impairment or dialysis, moderate or severe hepatic impairment, chronic intestinal disease (including ulcerative colitis and gastrointestinal obstruction), megacolon, diabetic neuropathy, oesophageal inflammation (hiatus hernia, gastrooesophageal reflux), Parkinsons disease, or other significant clinical condition (at the discretion of the investigator)
9. Other specific medications: anticholinergics, antispasmodics, anti-parkinsonian, tricyclics, tetracyclics, duloxetine, antihistamines, antiemetics, diuretics, neuroleptics, type I antiarrhythmics, opioids, alpha-antagonists, CYP3A4 inhibitors or inducers, any other bladder medication

At randomisation:
Failure to complete FVC according to instructions

Date of first enrolment

01/12/2005

Date of final enrolment

01/12/2007

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

8 Devonshire Place

London

United Kingdom

W1G 6HP

Sponsor information

Organisation

King's College London (UK)

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Industry

Funder Name

UCB Pharma (UK) - an investigator initiated study, meaning that investigators will 'own' the data, but UCB Pharma are funding on the assumption that the publication of the results will be of commercial benefit to them.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2011		Yes	No
Results article	results	01/05/2011		Yes	No
Results article	results	01/07/2011		Yes	No